Chemical meningitis related to intra-CSF liposomal cytarabine. (October 2017)

• Record Type: Journal Article
• Authors: Durand, Bénédicte; Zairi, Fahed; Boulanger, Thomas; Bonneterre, Jacques; Mortier, Laurent; Le Rhun, Emilie
• Is Part Of: CNS oncology. Volume 6:Number 4(2017)
• Page Start: 261
• Page End: 267
• Publication Date: 2017-10
• Subjects: leptomeningeal metastasis -- neoplastic meningitis -- toxicity; Central nervous system -- Tumors -- Periodicals; 616.99481
• DOI: 10.2217/cns-2016-0046
• Languages: English
• ISSNs: 2045-0907

Abstract

Therapeutic options of leptomeningeal metastases include intra-cerebrospinal fluid (CSF) chemotherapy. Among intra-CSF agents, liposomal cytarabine has advantages but can induce specific toxicities. A BRAF -V600E-mutated melanoma leptomeningeal metastases patient, treated by dabrafenib and liposomal cytarabine, presented after the first injection of liposomal cytarabine with hyperthermia and headaches. Despite sterile CSF/blood analyses, extended intravenous antibiotics were given and the second injection was delayed. The diagnosis of chemical meningitis was finally made. Dose reduction and appropriate symptomatic treatment permitted the administration of 15 injections of liposomal cytarabine combined with dabrafenib. A confirmation of the diagnosis of chemical meningitis is essential in order (1) not to delay intra-CSF or systemic chemotherapy or (2) to limit the administration of unnecessary but potentially toxic antibiotics.